基本信息来源于合作网站,原文需代理用户跳转至来源网站获取       
摘要:
Liver cancer is one of the most common causes of cancer death globally,and its incidence in the United States is increasing.Patients with advanced hepatocellular carcinoma(HCC)who are not candidates for surgical resection,liver transplant,or locoregional therapies can be treated with systemic therapies.Multiple agents,including sorafenib,lenvatinib,and regorafenib are approved for use as either first-or second-line therapy in this patient population,but all have relatively modest survival benefits.HCC is potentially susceptible to therapy with checkpoint inhibitors,including agents such as nivolumab and pembrolizumab,which are both approved by the Food and Drug Administration for patients previously treated with sorafenib but have not demonstrated superior overall survival in phase III trials.It is clear that more effective approaches are needed to potentiate the effects of checkpoint inhibitors in patients with HCC.This review will outline and appraise the current literature on the use of checkpoint inhibitors in HCC as part of a combination treatment involving an additional mode of therapy.The list of agents that can be paired with checkpoint inhibitors includes an additional checkpoint inhibitor,vascular endothelial growth factor or vascular endothelial growth factor receptor inhibitors,tyrosine kinase inhibitors,OX-40 agonists,and PT-112 inhibitors.The main non-pharmacologic therapies currently being studied for inclusion in a combination strategy include radiation therapy,trans-arterial chemoembolization,and ablation.
内容分析
关键词云
关键词热度
相关文献总数  
(/次)
(/年)
文献信息
篇名 Immunotherapy in hepatocellular carcinoma: Combination strategies
来源期刊 世界荟萃分析杂志 学科 医学
关键词 Hepatocellular carcinoma Liver neoplasms Antineoplastic agents IMMUNOLOGICAL Protein kinase inhibitors Angiogenesis inhibitors
年,卷(期) 2020,(3) 所属期刊栏目
研究方向 页码范围 190-209
页数 20页 分类号 R73
字数 语种
DOI
五维指标
传播情况
(/次)
(/年)
引文网络
引文网络
二级参考文献  (0)
共引文献  (0)
参考文献  (0)
节点文献
引证文献  (0)
同被引文献  (0)
二级引证文献  (0)
2020(0)
  • 参考文献(0)
  • 二级参考文献(0)
  • 引证文献(0)
  • 二级引证文献(0)
研究主题发展历程
节点文献
Hepatocellular
carcinoma
Liver
neoplasms
Antineoplastic
agents
IMMUNOLOGICAL
Protein
kinase
inhibitors
Angiogenesis
inhibitors
研究起点
研究来源
研究分支
研究去脉
引文网络交叉学科
相关学者/机构
期刊影响力
世界荟萃分析杂志
不定期
2308-3840
北京市朝阳区东四环中路62号楼远洋国际中
出版文献量(篇)
37
总下载数(次)
0
总被引数(次)
0
论文1v1指导